Timber Hill LLC bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 963 shares of the medical research company’s stock, valued at approximately $214,000.
Several other large investors have also recently bought and sold shares of the company. Advisors Asset Management Inc. increased its holdings in shares of Bio-Rad Laboratories by 6.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 19,051 shares of the medical research company’s stock valued at $4,234,000 after purchasing an additional 1,230 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Bio-Rad Laboratories by 1,262.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 22,703 shares of the medical research company’s stock valued at $5,045,000 after purchasing an additional 21,037 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Bio-Rad Laboratories by 7.1% during the 3rd quarter. Rhumbline Advisers now owns 44,579 shares of the medical research company’s stock valued at $9,906,000 after purchasing an additional 2,965 shares in the last quarter. Advisor Group Inc. increased its holdings in shares of Bio-Rad Laboratories by 121.8% during the 3rd quarter. Advisor Group Inc. now owns 2,112 shares of the medical research company’s stock valued at $470,000 after purchasing an additional 1,160 shares in the last quarter. Finally, Dorsey Wright & Associates increased its holdings in shares of Bio-Rad Laboratories by 98.6% during the 3rd quarter. Dorsey Wright & Associates now owns 15,783 shares of the medical research company’s stock valued at $3,507,000 after purchasing an additional 7,834 shares in the last quarter. 64.27% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Timber Hill LLC Purchases New Stake in Bio-Rad Laboratories, Inc. (BIO)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://sportsperspectives.com/2017/11/18/timber-hill-llc-purchases-new-stake-in-bio-rad-laboratories-inc-bio.html.
Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.54 by $0.37. The company had revenue of $535.00 million during the quarter, compared to analyst estimates of $507.99 million. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.62 EPS. equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 2.65 EPS for the current year.
In related news, EVP Giovanni Magni sold 2,400 shares of the business’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $253.01, for a total value of $607,224.00. Following the completion of the sale, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $2,340,595.51. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 28.29% of the stock is currently owned by insiders.
Several research firms have recently weighed in on BIO. TheStreet raised shares of Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a report on Monday, November 13th. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $255.00 target price on shares of Bio-Rad Laboratories in a report on Monday, September 18th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $260.00.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.